Literature DB >> 29212120

Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice.

Viola Lorenz1, Haley Ramsey1, Zhi-Jian Liu1, Joseph Italiano2, Karin Hoffmeister2,3, Sihem Bihorel4,5, Donald Mager4, Zhongbo Hu6, William B Slayton6, Benjamin T Kile7,8, Martha Sola-Visner1, Francisca Ferrer-Marin1,9.   

Abstract

Congenital amegakaryocytic thrombocytopaenia (CAMT) is a disorder caused by c-MPL mutations that impair thrombopoietin (TPO) signalling, resulting in a near absence of megakaryocytes (MKs). While this phenotype is consistent in adults, neonates with CAMT can present with severe thrombocytopaenia despite normal MK numbers. To investigate this, we characterized MKs and platelets in newborn c-MPL –/– mice. Liver MKs in c-MPL –/– neonates were reduced in number and size compared with wild-type (WT) age-matched MKs, and exhibited ultrastructural abnormalities not found in adult c-MPL –/– MKs. Platelet counts were lower in c-MPL –/– compared with WT mice at birth and did not increase over the first 2 weeks of life. In vivo biotinylation revealed a significant reduction in the platelet half-life of c-MPL –/– newborn mice (P2) compared with age-matched WT pups, which was not associated with ultrastructural abnormalities. Genetic deletion of the pro-apoptotic Bak did not rescue the severely reduced platelet half-life of c-MPL –/– newborn mice, suggesting that it was due to factors other than platelets entering apoptosis early. Indeed, adult GFP+ (green fluorescent protein transgenic) platelets transfused into thrombocytopenic c-MPL –/– P2 pups also had a shortened lifespan, indicating the importance of cell-extrinsic factors. In addition, neonatal platelets from WT and c-MPL –/– mice exhibited reduced P-selectin surface expression following stimulation compared with adult platelets of either genotype, and platelets from c-MPL –/– neonates exhibited reduced glycoprotein IIb/IIIa (GPIIb/IIIa) activation in response to thrombin compared with age-matched WT platelets. Taken together, our findings indicate that c-MPL deficiency is associated with abnormal maturation of neonatal MKs and developmental stage-specific defects in platelet function.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29212120      PMCID: PMC5911346          DOI: 10.1160/TH17-06-0433

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  49 in total

1.  Normal platelets and megakaryocytes are produced in vivo in the absence of thrombopoietin.

Authors:  S Bunting; R Widmer; T Lipari; L Rangell; H Steinmetz; K Carver-Moore; M W Moore; G A Keller; F J de Sauvage
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

2.  Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways.

Authors:  Keita Kirito; Tomoko Watanabe; Ken-ichi Sawada; Hitoshi Endo; Keiya Ozawa; Norio Komatsu
Journal:  J Biol Chem       Date:  2001-12-27       Impact factor: 5.157

3.  Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival.

Authors:  Marlyse A Debrincat; Emma C Josefsson; Chloé James; Katya J Henley; Sarah Ellis; Marion Lebois; Kelly L Betterman; Rachael M Lane; Kelly L Rogers; Michael J White; Andrew W Roberts; Natasha L Harvey; Donald Metcalf; Benjamin T Kile
Journal:  Blood       Date:  2012-02-28       Impact factor: 22.113

4.  A mutation in the translation initiation codon of Gata-1 disrupts megakaryocyte maturation and causes thrombocytopenia.

Authors:  Ian J Majewski; Donald Metcalf; Lisa A Mielke; Danielle L Krebs; Sarah Ellis; Marina R Carpinelli; Sandra Mifsud; Ladina Di Rago; Jason Corbin; Nicos A Nicola; Douglas J Hilton; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

5.  Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin.

Authors:  M C Sola; Y Du; A D Hutson; R D Christensen
Journal:  Br J Haematol       Date:  2000-08       Impact factor: 6.998

Review 6.  Congenital amegakaryocytic thrombocytopenia and thrombocytopenia with absent radii.

Authors:  Amy E Geddis
Journal:  Hematol Oncol Clin North Am       Date:  2009-04       Impact factor: 3.722

7.  MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease.

Authors:  Manuela Germeshausen; Matthias Ballmaier; Karl Welte
Journal:  Hum Mutat       Date:  2006-03       Impact factor: 4.878

8.  Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.

Authors:  W S Alexander; A W Roberts; N A Nicola; R Li; D Metcalf
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

9.  Congenital amegakaryocytic thrombocytopenia: the diagnostic importance of combining pathology with molecular genetics.

Authors:  Melissa J Rose; Kathleen K Nicol; Micah A Skeens; Thomas G Gross; Bryce A Kerlin
Journal:  Pediatr Blood Cancer       Date:  2008-06       Impact factor: 3.167

10.  Platelet Transfusion Practices Among Very-Low-Birth-Weight Infants.

Authors:  Katherine A Sparger; Susan F Assmann; Suzanne Granger; Abigail Winston; Robert D Christensen; John A Widness; Cassandra Josephson; Sean R Stowell; Matthew Saxonhouse; Martha Sola-Visner
Journal:  JAMA Pediatr       Date:  2016-07-01       Impact factor: 16.193

View more
  9 in total

Review 1.  Changes in megakaryopoiesis over ontogeny and their implications in health and disease.

Authors:  Patricia Davenport; Zhi-Jian Liu; Martha Sola-Visner
Journal:  Platelets       Date:  2020-03-21       Impact factor: 3.862

2.  Fetal vs adult megakaryopoiesis.

Authors:  Patricia Davenport; Zhi-Jian Liu; Martha Sola-Visner
Journal:  Blood       Date:  2022-06-02       Impact factor: 25.476

3.  Dynamin 2 is required for GPVI signaling and platelet hemostatic function in mice.

Authors:  Nathan Eaton; Caleb Drew; Jon Wieser; Adam D Munday; Hervé Falet
Journal:  Haematologica       Date:  2019-07-11       Impact factor: 9.941

4.  Therapeutic Effects and Associated Mechanisms by which "Fuyang Jiedu Huayu" Granules Treat Chronic Liver Failure in the Rat.

Authors:  Qianling Ye; Hainan Jiang; Yanmei Lan; Minggang Wang; Dewen Mao
Journal:  Evid Based Complement Alternat Med       Date:  2021-04-17       Impact factor: 2.629

5.  Endocytosis of the thrombopoietin receptor Mpl regulates megakaryocyte and erythroid maturation in mice.

Authors:  Nathan Eaton; Emily K Boyd; Ratnashree Biswas; Melissa M Lee-Sundlov; Theresa A Dlugi; Haley E Ramsey; Shikan Zheng; Robert T Burns; Martha C Sola-Visner; Karin M Hoffmeister; Hervé Falet
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

6.  Bleeding diathesis in mice lacking JAK2 in platelets.

Authors:  Nathan Eaton; Saravanan Subramaniam; Marie L Schulte; Caleb Drew; David Jakab; Sandra L Haberichter; Hartmut Weiler; Hervé Falet
Journal:  Blood Adv       Date:  2021-08-10

7.  Development of gates to measure the immature platelet fraction in C57BL/6J mice using the Sysmex XN-V series multispecies hematology analyzer.

Authors:  Patricia Davenport; Viola Lorenz; Zhi-Jian Liu; Henry A Feldman; Jorge Canas; Emily Nolton; Chiara-Aiyleen Badur; Thi Minh-Thi Do; Martha Sola-Visner
Journal:  J Vet Diagn Invest       Date:  2021-07-05       Impact factor: 1.569

8.  Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia.

Authors:  Alexander T Hardy; Verónica Palma-Barqueros; Stephanie K Watson; Jean-Daniel Malcor; Johannes A Eble; Elizabeth E Gardiner; José E Blanco; Rafael Guijarro-Campillo; Juan L Delgado; María L Lozano; Raúl Teruel-Montoya; Vicente Vicente; Steve P Watson; José Rivera; Francisca Ferrer-Marín
Journal:  Thromb Haemost       Date:  2018-04-25       Impact factor: 5.249

9.  CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients.

Authors:  Manuela Germeshausen; Matthias Ballmaier
Journal:  Haematologica       Date:  2021-09-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.